FIP1L1-PDGFRA fusion gene in T-lymphoblastic lymphoma: A case report.

Salhah AliYasmine Al-QattanWalaa AwnyAbdulaziz HamadahKaren PintoSalem AlShemmari

Published in: Cancer reports (Hoboken, N.J.) (2022)

FIP1L1-PDGFRA-positive T-LBL and myeloproliferative disorders have excellent response to low-dose treatment with (TKI) imatinib. Most patients achieve rapid and complete hematologic and molecular remission within weeks.

Keyphrases

low dose
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
prognostic factors
diffuse large b cell lymphoma
high dose
peritoneal dialysis
tyrosine kinase
systemic lupus erythematosus
rheumatoid arthritis
gene expression
patient reported outcomes
combination therapy